These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 5010762)

  • 41. [Peculiarities of the clinical picture of peripheral arterial insufficiency depending on the age of patients].
    Kaniak J; Knapik Z; Wlodarczykowa J
    Pol Tyg Lek; 1969 May; 24(19):719-21. PubMed ID: 5804312
    [No Abstract]   [Full Text] [Related]  

  • 42. [31P magnetic resonance spectroscopy: a noninvasive method for studying skeletal muscle metabolism in patients with arteriosclerosis obliterans of the vessels of the lower extremities and for assessing the efficacy of vasoprostan therapy].
    Sinitsyn VE; Veselova TN; Bakharev AO; Karpov IuA
    Ter Arkh; 1996; 68(12):69-72. PubMed ID: 9054047
    [No Abstract]   [Full Text] [Related]  

  • 43. Hypervolemic treatment of the chronic obliterative arteriopathies of extremities.
    Brassai Z; Koválszki P; Pop GH; Kiss K; Olosz E
    Med Interne; 1986; 24(1):37-41. PubMed ID: 2422732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pyridinolcarbamate, bradykinin antagonist, in patients suffering from arteriosclerosis obliterans and thromboangiitis obliterans (Buerger's disease); a preliminary report on the treatment of human atherosclerosis.
    Shimamoto T; Atsumi T
    Jpn Heart J; 1965 Sep; 6(5):407-15. PubMed ID: 5294603
    [No Abstract]   [Full Text] [Related]  

  • 45. [Taurine in the therapy of obliterating arteriopathy of the lower extremities. I. Clinical results in various evolutive phases].
    Zanelli G; Ferrero S; Patrone P
    Minerva Cardioangiol; 1971 Nov; 19(11):605-15. PubMed ID: 5128422
    [No Abstract]   [Full Text] [Related]  

  • 46. [Evaluation of a single infusion of low-molecular dextran in patients with chronic obliterative arterial diseases].
    Chrzanowski W
    Pol Tyg Lek; 1969 Jul; 24(27):1057-9. PubMed ID: 4896578
    [No Abstract]   [Full Text] [Related]  

  • 47. [Hemokinetic and metabolic action of 7-2-(3-pyridyl-methylamino)-ethyl-theophylline nicotinate as a basis of medical treatment of chronic obliterating peripheral arteriopathy].
    Cascio F
    Minerva Cardioangiol; 1973 Nov; 21(11):715-31. PubMed ID: 4776567
    [No Abstract]   [Full Text] [Related]  

  • 48. The role of phenformin and ethyloestrenol or stanozolol in the treatment of decreased fibrinolytic states. (Cutaneous vasculitis, Raynaud's disease, Behcet's syndrome, recurrent deep vein thrombosis and post myocardial infarction).
    Menon IS
    Acta Univ Carol Med Monogr; 1972; 52():19-23. PubMed ID: 4669824
    [No Abstract]   [Full Text] [Related]  

  • 49. The excretion of 5-hydroxyindoleacetic acid in normal and vascular deficient human subjects.
    Zawrocka-Wrzolkowa T
    Bull Acad Pol Sci Biol; 1965; 13(10):619-21. PubMed ID: 5887195
    [No Abstract]   [Full Text] [Related]  

  • 50. [Therapeutic properties of xanthine nicotinate in the treatment of obliterating arteriopathies].
    Tardito E; Azzolini A; De Cristofaro A; Papacharalambus D
    Minerva Cardioangiol; 1972; 20(7):369-89. PubMed ID: 5050745
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinical effect of O-betahydroxyethyl-rutosides (HR) in patients with occlusive arterial disease.
    Bielawiec M; Lukjan H; Grabowski R; Myśliwiec M; Korfel B
    Bibl Anat; 1977; (16 Pt 2):152-4. PubMed ID: 603503
    [No Abstract]   [Full Text] [Related]  

  • 52. [Contents of cyclic nucleotides in blood and tissues in ischemia of the lower limbs].
    Zoloev GK; Rikitin VA; Argintaev ES; Shil'nikov MG; Pavlenko VS
    Kardiologiia; 1993; 33(1):60-2. PubMed ID: 8035549
    [No Abstract]   [Full Text] [Related]  

  • 53. [Clinical evaluation of the preparation Trental].
    Wesołowski J; Hubl S; Szubski J; Weinzieher E; Rykowski H
    Wiad Lek; 1985 Apr; 38(8):551-5. PubMed ID: 3892924
    [No Abstract]   [Full Text] [Related]  

  • 54. [Treatment of organic diseases of peripheral arteries with nicotinic acid derivatives].
    Liszewska D; Lukasik E
    Pol Tyg Lek; 1967 May; 22(21):794-6. PubMed ID: 6041002
    [No Abstract]   [Full Text] [Related]  

  • 55. [Clinical evaluation of Provasan].
    Wodniecki J; Wolański A
    Wiad Lek; 1970 Oct; 23(20):1791-3. PubMed ID: 5482235
    [No Abstract]   [Full Text] [Related]  

  • 56. Chronic venous insufficiency treated with hydroxyethylrutosides (HR).
    Sorensen AH; Hansen H
    Angiologica; 1970; 7(3):187-92. PubMed ID: 4913054
    [No Abstract]   [Full Text] [Related]  

  • 57. The influence of long-term therapy with phenformin plus metanabol on blood fibrinolytic activity, platelet adhesiveness and lipid metabolism in patients with arteriosclerosis.
    Perzanowski A; Bielawiec M; Myśliwiec M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(3):381-8. PubMed ID: 63425
    [No Abstract]   [Full Text] [Related]  

  • 58. [Medical therapy of obliterating arteriopathies].
    Schwarz D
    Minerva Med; 1969 Oct; 60(87):4335-44. PubMed ID: 4242895
    [No Abstract]   [Full Text] [Related]  

  • 59. [Prostaglandin E1 in the treatment of chronic ischemia of the extremities].
    Kowal-Gierczak B; Kurzawska-Mielecka M; Czarnacki M
    Pol Arch Med Wewn; 1990 Nov; 84(5):321-7. PubMed ID: 2075125
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Serum lipid levels in patients with arteriosclerosis obliterans of the legs during treatment with pentoxifylline].
    Kuczyńska K; Zebrowski M; Kancelarczyk WL; Rymaszewski Z
    Pol Tyg Lek; 1988 Aug; 43(34):1092-4. PubMed ID: 3075031
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.